In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:Epidemiology and burden of nosocomial bacterial pneumoniaPatient-specific risk factors for MDR pathogensImproving outcomes with the use of antibiogramsRecommended empiric therapy for clinically suspected VABPAntimicrobial resistance in HABP/VABPAlgorithms for gram-negative organism antibiotic-susceptibility testingUsing rapid diagnostic tests for HABP/VABPNew antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:ASPECT-NP: ceftolozane/tazobactam vs meropenemREPROVE: ceftazidime/avibactam vs meropenemRESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenemRESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactamAPEKS-NP: cefiderocol vs meropenemCREDIBLE-CR: cefiderocol vs best available therapyProgram Director:Keith S. Kaye, MD, MPHChiefDivision of Allergy, Immunology and Infectious DiseasesProfessor of MedicineRutgers Robert Wood Johnson Medical SchoolNew Brunswick, New JerseyFaculty:Lilian Abbo, MD, FIDSAAssociate Chief Medical Officer in Infectious DiseasesJackson Health SystemProfessor of Infectious DiseasesDepartment of Medicine & Miami Transplant InstituteUniversity of Miami Miller School of MedicineMiami, FloridaJason M. Pogue, PharmDClinical ProfessorDepartment of Clinical PharmacyUniversity of Michigan College of PharmacyInfectious Diseases Clinical PharmacistMichigan MedicineAnn Arbor, MichiganContent based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.Follow along with a downloadable slideset at:https://bit.ly/3CEop6hLink to full program https://bit.ly/3i781lf Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related